JP2011526792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526792A5 JP2011526792A5 JP2011516886A JP2011516886A JP2011526792A5 JP 2011526792 A5 JP2011526792 A5 JP 2011526792A5 JP 2011516886 A JP2011516886 A JP 2011516886A JP 2011516886 A JP2011516886 A JP 2011516886A JP 2011526792 A5 JP2011526792 A5 JP 2011526792A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- domain
- multispecific fusion
- antagonist
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 34
- 108020001507 fusion proteins Proteins 0.000 claims description 34
- 239000005557 antagonist Substances 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102100033461 Interleukin-17A Human genes 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 229940124044 RANKL antagonist Drugs 0.000 claims description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 7
- 230000009870 specific binding Effects 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13409808P | 2008-07-02 | 2008-07-02 | |
| US13410008P | 2008-07-02 | 2008-07-02 | |
| US13409608P | 2008-07-02 | 2008-07-02 | |
| US13409508P | 2008-07-02 | 2008-07-02 | |
| US13410108P | 2008-07-02 | 2008-07-02 | |
| US13409708P | 2008-07-02 | 2008-07-02 | |
| US13409908P | 2008-07-02 | 2008-07-02 | |
| US61/134,097 | 2008-07-02 | ||
| US61/134,098 | 2008-07-02 | ||
| US61/134,095 | 2008-07-02 | ||
| US61/134,101 | 2008-07-02 | ||
| US61/134,099 | 2008-07-02 | ||
| US61/134,096 | 2008-07-02 | ||
| US61/134,100 | 2008-07-02 | ||
| US18009709P | 2009-05-20 | 2009-05-20 | |
| US61/180,097 | 2009-05-20 | ||
| PCT/US2009/049603 WO2010003108A2 (en) | 2008-07-02 | 2009-07-02 | TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526792A JP2011526792A (ja) | 2011-10-20 |
| JP2011526792A5 true JP2011526792A5 (cg-RX-API-DMAC7.html) | 2012-08-16 |
Family
ID=41051379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516886A Pending JP2011526792A (ja) | 2008-07-02 | 2009-07-02 | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110152173A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2310410A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011526792A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110044991A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102171247A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009266863A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0914005A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2729749A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201170028A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL210264A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011000041A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ590668A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010003108A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004085648A2 (en) | 2003-03-19 | 2004-10-07 | Biogen Idec Ma Inc. | Nogo receptor binding protein |
| BRPI0512500A (pt) | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
| RS53058B (sr) | 2005-07-08 | 2014-04-30 | Biogen Idec Ma Inc. | Sp35 antitela i njihova primena |
| SG174053A1 (en) | 2006-09-01 | 2011-09-29 | Therapeutic Human Polyclonals Inc | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| CN102264390A (zh) * | 2008-07-02 | 2011-11-30 | 新兴产品开发西雅图有限公司 | Il6免疫治疗 |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| CN105218673A (zh) * | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
| EP2516467A2 (en) * | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| KR101004363B1 (ko) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제 |
| KR101004362B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 |
| KR101712874B1 (ko) * | 2010-09-30 | 2017-03-07 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 인간화 항 TNF α 항체 및 그의 항원 결합 단편 (Fab) 및 용도 |
| US9527905B2 (en) | 2011-02-08 | 2016-12-27 | Medimmune, Llc | Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use |
| EP2784080B1 (en) * | 2011-10-31 | 2019-12-18 | Shimadzu Corporation | Peptide-hinge-free flexible antibody-like molecule |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| EP2791338B1 (en) * | 2011-12-15 | 2019-02-20 | The Royal Institution for the Advancement of Learning / McGill University | Soluble igf receptor fc fusion proteins and uses thereof |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| MX2014011818A (es) | 2012-04-05 | 2014-12-10 | Hoffmann La Roche | Anticuerpos biespecificos contra inductor debil de la apoptosis relacionado con el tnf (tweak) humana e il17 humana y usos de los mismos. |
| US10202452B2 (en) | 2012-04-20 | 2019-02-12 | Aptevo Research And Development Llc | CD3 binding polypeptides |
| CN104583239B (zh) | 2012-05-10 | 2018-09-18 | 生物蛋白有限公司 | 多特异单克隆抗体 |
| EP2849787A4 (en) | 2012-05-14 | 2016-06-15 | Biogen Ma Inc | LINGO-2 ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING ENGINE NEURONS |
| WO2014106001A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
| CN103060274B (zh) * | 2012-12-28 | 2013-12-11 | 首都医科大学 | Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用 |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| WO2015065987A1 (en) | 2013-11-01 | 2015-05-07 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| MX2017009038A (es) | 2015-01-08 | 2017-10-25 | Biogen Ma Inc | Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes. |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| MX2018001566A (es) | 2015-08-07 | 2019-04-25 | Imaginab Inc | Construcciones de union a antigeno para moleculas diana. |
| EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3-BINDING POLYPEPTIDES |
| WO2017072208A1 (en) * | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Transgenic rabbit with common light chain |
| EP3293293A1 (en) * | 2016-09-08 | 2018-03-14 | Italfarmaco SpA | Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| AU2018275359C1 (en) | 2017-06-02 | 2022-02-03 | Pfizer Inc. | Antibodies specific for FLT3 and their uses |
| JP6895165B2 (ja) * | 2017-06-06 | 2021-06-30 | 知和 松浦 | α１−アンチキモトリプシンを含むバイオマーカー |
| WO2019016402A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO |
| CA3103414A1 (en) | 2018-06-14 | 2019-12-19 | Bioatla, Inc. | Multi-specific antibody constructs |
| EP3840838A2 (en) | 2018-07-24 | 2021-06-30 | MedImmune, LLC | Antibody directed against s.aureus clumping factor a (clfa) |
| JP2022512647A (ja) | 2018-10-09 | 2022-02-07 | メディミューン，エルエルシー | 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ |
| KR102404684B1 (ko) * | 2019-01-15 | 2022-06-07 | 서울대학교산학협력단 | 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
| WO2021030488A1 (en) | 2019-08-12 | 2021-02-18 | Bienvenue David Leonard | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
| JP2023512454A (ja) | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | タンパク質治療のための製剤 |
| CA3197104A1 (en) * | 2020-11-11 | 2022-05-19 | Hq Han | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |
| CN112451670B (zh) * | 2020-11-25 | 2024-01-02 | 沣潮医药科技（上海）有限公司 | 异位内膜治疗的组合物和预后检测试剂盒 |
| IL303328A (en) | 2020-12-01 | 2023-07-01 | Aptevo Res & Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| CA3219832A1 (en) | 2021-05-21 | 2022-11-24 | Fatih Uckun | Dosing regimens for protein therapeutics |
| CN117136196A (zh) * | 2022-03-03 | 2023-11-28 | 上海赛金生物医药有限公司 | 一种重组融合蛋白的制剂 |
| US20250197475A1 (en) * | 2022-03-18 | 2025-06-19 | Fab Biopharma, Inc. | Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus |
| CN120584137A (zh) | 2023-01-06 | 2025-09-02 | 阿帕特夫研究和发展有限公司 | 双特异性pd-l1和cd40结合分子以及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| JP3887011B2 (ja) * | 1992-12-29 | 2007-02-28 | ジェネンテク，インコーポレイテッド | ＩＦＮ−γインヒビターによる炎症性腸疾患の処置 |
| US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| HK1038755A1 (zh) * | 1999-01-15 | 2002-03-28 | Biogen, Inc. | Tweak及tweak受体对抗物和使用对抗物治疗免疫失常症 |
| US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| WO2002094192A2 (en) * | 2001-05-24 | 2002-11-28 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| DE10148217C1 (de) * | 2001-09-28 | 2003-04-24 | Bosch Gmbh Robert | Verfahren, Computerprogramm und Steuer- und/oder Regelgerät zum Betreiben einer Brennkraftmaschine, sowie Brennkraftmaschine |
| ES2365606T3 (es) * | 2002-02-13 | 2011-10-07 | Ludwig Institute For Cancer Research Ltd. | Anticuerpos contra gm-csf quiméricos. |
| CN1692127A (zh) * | 2002-07-25 | 2005-11-02 | 健泰科生物技术公司 | Taci抗体及其用途 |
| JP2008500830A (ja) * | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
| CA2583937A1 (en) * | 2004-10-12 | 2006-04-27 | Amprotein Corporation | Chimeric protein |
| WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| DK1866339T3 (da) * | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| NZ564027A (en) * | 2005-05-18 | 2011-06-30 | Morphosys Ag | Anti-GM-CSF antibodies and uses therefor |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| RU2515108C2 (ru) * | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| BRPI0707425A2 (pt) * | 2006-02-01 | 2011-05-03 | Arana Therapeutics Ltd | construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CN102264390A (zh) * | 2008-07-02 | 2011-11-30 | 新兴产品开发西雅图有限公司 | Il6免疫治疗 |
| CA2729810A1 (en) * | 2008-07-02 | 2010-01-07 | Emergent Product Development Seattle, Llc | Tgf-.beta. antagonist multi-target binding proteins |
| EP2321345A1 (en) * | 2008-07-28 | 2011-05-18 | Emergent Product Development Seattle, LLC | Multi-specific binding proteins targeting b cell disorders |
| KR20180105731A (ko) * | 2008-10-02 | 2018-09-28 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Ｃｄ86 길항제 다중-표적 결합 단백질 |
| CN105218673A (zh) * | 2008-10-10 | 2016-01-06 | 新兴产品开发西雅图有限公司 | Tcr复合物免疫治疗剂 |
-
2009
- 2009-07-02 EA EA201170028A patent/EA201170028A1/ru unknown
- 2009-07-02 EP EP09774557A patent/EP2310410A2/en not_active Withdrawn
- 2009-07-02 BR BRPI0914005A patent/BRPI0914005A2/pt not_active IP Right Cessation
- 2009-07-02 US US13/001,087 patent/US20110152173A1/en not_active Abandoned
- 2009-07-02 NZ NZ590668A patent/NZ590668A/xx not_active IP Right Cessation
- 2009-07-02 AU AU2009266863A patent/AU2009266863A1/en not_active Abandoned
- 2009-07-02 CN CN2009801338489A patent/CN102171247A/zh active Pending
- 2009-07-02 JP JP2011516886A patent/JP2011526792A/ja active Pending
- 2009-07-02 WO PCT/US2009/049603 patent/WO2010003108A2/en not_active Ceased
- 2009-07-02 MX MX2011000041A patent/MX2011000041A/es not_active Application Discontinuation
- 2009-07-02 CA CA2729749A patent/CA2729749A1/en not_active Abandoned
- 2009-07-02 KR KR1020117002700A patent/KR20110044991A/ko not_active Withdrawn
-
2010
- 2010-12-26 IL IL210264A patent/IL210264A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526792A5 (cg-RX-API-DMAC7.html) | ||
| AU2016262662B2 (en) | Antibodies that bind csf1r | |
| JP2015524799A5 (cg-RX-API-DMAC7.html) | ||
| US20140193408A1 (en) | Soluble proteins for use as therapeutics | |
| KR20230029621A (ko) | T 세포 억제 단백질을 포함하거나 포함하지 않는 april 및 baff 억제 면역조절 단백질 및 이의 사용 방법 | |
| JP2014503209A5 (cg-RX-API-DMAC7.html) | ||
| JP2011526794A5 (cg-RX-API-DMAC7.html) | ||
| JP6943764B2 (ja) | Ｉｌ−１７ａ結合ポリペプチド | |
| JP2014518883A5 (cg-RX-API-DMAC7.html) | ||
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| PT2697257T (pt) | Proteínas de fusão fc compreendendo novos ligantes ou arranjos | |
| RS61493B1 (sr) | Konstrukti multispecifičnih antitela | |
| CN102770537A (zh) | 用于纯化多肽多聚体的多肽的修饰方法 | |
| JP2013529070A5 (cg-RX-API-DMAC7.html) | ||
| AU2009266863A1 (en) | TNF-alpha antagonist multi-target being proteins | |
| JP2016510743A (ja) | 抗ｔｎｆ−抗ｉｌ−１７二重特異性抗体 | |
| JP2016513669A5 (cg-RX-API-DMAC7.html) | ||
| JP2022528324A (ja) | 抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療 | |
| EP3986920B1 (en) | Tnfr2 agonists with improved stability | |
| BR112020025030A2 (pt) | anticorpos que compreendem um polipeptídeo inserido na região de framework 3 | |
| CN108473571A (zh) | 结合人Fc受体的融合蛋白 | |
| WO2019096026A1 (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| Richter et al. | Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity | |
| JP2014124186A (ja) | 多価抗体フラグメントおよびその三量体化複合体 |